Latest Regulatory News

Antaria has disclosed several FDA-identified GMP compliance issues but assures no impact on product quality or supply, committing to expert-led remediation and enhanced training.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Airtasker Limited has announced a $10 million equity capital raise to accelerate marketing efforts in the UK and US, following a strong first quarter with group revenue up 20.5% year-on-year. Strategic partnerships, including a cornerstone investment from iHeartMedia, underpin its international growth ambitions.

Genmin Limited has launched a A$25.7 million equity raising to advance its Baniaka iron ore project in Gabon, aiming for a final investment decision by mid-2026. The raise includes strategic collaboration with PowerChina and offers attaching options to investors.

Patriot Resources reports significant copper-zinc-lead assay results from its Phase 1 trenching at Kitumba, Zambia, expanding the mineralised footprint fivefold and setting the stage for further exploration.

Aurora Labs has entered a strategic MOU with Ares Armaments to co-develop advanced metal components for defence, aiming to revolutionise small-arms manufacturing with additive technology.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Spacetalk launches its subscription-based Freedom Platform, aiming to transform family safety tech and hit $20-25 million in annual recurring revenue by 2026. The new app connects multiple generations, expanding beyond smartwatches into a broader digital ecosystem.

Bryah Resources has secured approvals and land access agreements to begin drilling at its Golden Pike Project in Canada, targeting high-grade gold and antimony deposits with programs set to complete by year-end.

Diablo Resources has appointed Matthew Blumberg as a Non-Executive Director and brought on Ellis Martin as its U.S. Media and Investor Communications Advisor, signaling a strategic push into North American markets.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.